 Investigators hypothesize that large scale assessment of cancer-specific DNA changes and rearrangements in the urine and plasma of prostate cancer patients using technology developed by our group qMBD-seq, will allow for more informative and accurate tracking of disease burden and therapeutic response in men receiving radiation therapy and ADT for high-risk prostate cancer. 